https://adipopharma.com/press-release/diabetes-adipopharmas-first-in-class-candidate-patas-shows-improvement-in-whole-body-insulin-resistance-and-associated-comorbidities-in-vivo/2022-07-13T01:22:49+00:00https://adipopharma.com/press-release/vers-une-nouvelle-classe-de-medicament-pour-traiter-le-diabete-de-type-2/2022-07-13T01:24:58+00:00https://adipopharma.com/press-release/vers-une-nouvelle-classe-de-medicament-pour-traiter-le-diabete-de-type-2-2/2022-07-13T01:26:28+00:00https://adipopharma.com/press-release/type-2-diabetes-drug-restores-fat-cells-glucose-management/2022-07-13T01:27:58+00:00https://adipopharma.com/press-release/towards-a-new-drug-class-in-the-treatment-of-type-2-diabetes/2022-07-13T01:29:41+00:00https://adipopharma.com/press-release/aurobac-therapeutics-boehringer-ingelheim-evotec-biomerieux-adipopharma-vincent-marion-integragen-oncodna/2022-07-13T01:31:59+00:00https://adipopharma.com/press-release/diabetes-adipopharmas-first-in-class-candidate-patas-shows-improvement-in-whole-body-insulin-resistance-and-associated-comorbidities-in-vivo-2/2022-07-13T01:33:19+00:00https://adipopharma.com/press-release/multinational-research-collab-develops-new-peptide-capable-of-repairing-metabolic-abnormalities-leading-to-type-2-diabetes-associated-comorbidities/2022-07-13T01:34:55+00:00https://adipopharma.com/press-release/towards-a-new-drug-class-in-the-treatment-of-type-2-diabetes-2/2022-07-14T01:35:27+00:00https://adipopharma.com/press-release/other-news-to-note-for-july-14-2022/2022-07-14T01:36:59+00:00https://adipopharma.com/press-release/adipopharmas-first-in-class-candidate-patas-shows-improvement-in-whole-body-insulin-resistance-and-associated-comorbidities-in-vivo/2022-07-15T01:38:03+00:00https://adipopharma.com/press-release/diabetes%ef%bc%9a%e4%b8%80%e7%a7%8d%e6%b2%bb%e7%96%972%e5%9e%8b%e7%b3%96%e5%b0%bf%e7%97%85%e7%9a%84%e6%96%b0%e8%8d%af/2022-07-15T01:39:00+00:00https://adipopharma.com/press-release/vers-une-nouvelle-classe-de-medicament-pour-traiter-le-diabete-de-type-2-3/2022-07-18T01:40:05+00:00https://adipopharma.com/press-release/diabete-de-type-2-cibler-la-resistance-a-linsuline-plutot-que-lhyperglycemie/2022-07-19T01:40:58+00:00https://adipopharma.com/press-release/%eb%8b%b9%eb%87%a8-%ec%b9%98%eb%a3%8c-%ec%8b%a0%ec%84%b8%ea%b3%84-%ec%8b%9c%ec%9e%91-%ec%9d%b8%ec%8a%90%eb%a6%b0-%ec%a0%80%ed%95%ad%ec%84%b1-%ed%91%9c%ec%a0%81-%ec%b5%9c%ec%b4%88-%ed%9b%84%eb%b3%b4/2022-07-19T01:41:58+00:00https://adipopharma.com/press-release/to-treat-insulin-resistance/2022-07-19T01:43:09+00:00https://adipopharma.com/press-release/diabete-de-type-2-cibler-la-resistance-a-linsuline-plutot-que-lhyperglycemie-2/2022-07-19T01:44:19+00:00https://adipopharma.com/press-release/towards-a-new-drug-class-in-the-treatment-of-type-2-diabetes-3/2022-07-20T02:05:49+00:00https://adipopharma.com/press-release/monash-university-towards-a-new-drug-class-in-the-treatment-of-type-2-diabetes/2022-07-22T02:06:52+00:00https://adipopharma.com/press-release/towards-a-new-drug-class-in-the-treatment-of-type-2-diabetes-4/2022-08-01T02:08:03+00:00https://adipopharma.com/press-release/new-medicine-class-to-treat-type-2-diabetes/2022-08-01T02:09:07+00:00https://adipopharma.com/press-release/adipopharma-targets-root-cause-of-diabetes-with-first-adipeutic-drug-candidate/2022-08-05T02:10:12+00:00https://adipopharma.com/press-release/first-in-class-synthetic-peptide-patas-promotes-insulin-free-glucose-absorption/2022-08-11T02:11:42+00:00https://adipopharma.com/press-release/diabetes-drug-to-correct-metabolic-abnormalities/2022-09-02T02:13:30+00:00https://adipopharma.com/press-release/new-treatment-set-to-benefit-1-in-20-australians-living-with-diabetes/2022-09-02T02:15:04+00:00https://adipopharma.com/press-release/la-societe-biotechnologique-francaise-adipopharma-obtient-un-financement-de-serie-a-pour-un-medicament-revolutionnaire-contre-le-diabete/2023-01-23T02:16:23+00:00https://adipopharma.com/press-release/french-biotech-company-adipopharma-wins-series-a-funding-for-breakthrough-diabetes-drug/2023-01-23T02:17:25+00:00https://adipopharma.com/press-release/french-biotech-company-adipopharma-secures-series-a-funding-for-breakthrough-diabetes-drug/2023-01-23T02:18:31+00:00https://adipopharma.com/press-release/series-a-for-adipopharma-to-advance-drug-for-root-cause-of-type-2-diabetes/2023-01-23T02:20:08+00:00https://adipopharma.com/press-release/la-societe-biotechnologique-francaise-adipopharma-obtient-un-financement-de-serie-a-pour-un-medicament-revolutionnaire-contre-le-diabete-2/2023-01-23T02:21:03+00:00https://adipopharma.com/press-release/french-biotech-company-adipopharma-secures-series-a-funding-for-groundbreaking-diabetes-drug/2023-01-23T02:21:54+00:00https://adipopharma.com/press-release/adipopharma-boucle-un-tour-de-table-pour-son-medicament-contre-le-diabete/2023-01-24T02:22:32+00:00https://adipopharma.com/press-release/la-biotech-alsacienne-adipopharma-et-sa-molecule-miracle-a-la-conquete-de-lamerique/2023-02-09T02:23:49+00:00https://adipopharma.com/press-release/french-biotech-company-adipopharma-secures-funding-to-initiate-clinical-trials-for-its-first-in-class-compound-for-insulin-resistance/2024-11-12T02:25:47+00:00https://adipopharma.com/press-release/adipopharma-obtient-un-financement-pour-lancer-les-essais-cliniques-de-sa-molecule-la-premiere-de-sa-categorie-pour-traiter-la-resistance-a-linsuline/2024-11-12T02:27:00+00:00https://adipopharma.com/press-release/adipopharma-recognized-at-american-diabetes-association-85th-annual-meeting-for-patas-its-first-in-class-whole-body-insulin-sensitizing-compound/2025-07-08T16:58:23+00:00https://adipopharma.com/press-release/1591/2026-03-24T13:24:35+00:00https://adipopharma.com/press-release/could-a-new-weight-loss-approach-have-longer-term-benefits-than-glp-1s/2026-11-02T09:31:27+00:00https://adipopharma.com/press-release/adipopharma-advances-patas-into-phase-1b-clinical-trial-in-patients-with-type-2-diabetes/2026-11-02T09:31:52+00:00https://adipopharma.com/press-release/adipopharma-advances-patas-into-phase-1b-clinical-trial-in-patients-with-type-2-diabetes-2/2026-11-02T09:32:10+00:00https://adipopharma.com/press-release/adipopharma-lance-la-phase-1b-des-essais-cliniques-du-peptide-patas-chez-des-patients-atteints-de-diabete-de-type-2/2026-11-02T09:32:27+00:00https://adipopharma.com/press-release/adipopharma-begins-phase-1b-dosing-of-insulin-sensitiser-patas-in-type-2-diabetes/2026-11-02T09:32:40+00:00